Establishing a Validation Framework of Treatment Discontinuation in Claims Data Using Natural Language Processing and Electronic Health Records
Clinical Pharmacology & Therapeutics · 2025-07 · 118 (1) · 138-145
DOI: 10.1002/cpt.3650 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 08.04.2025. Verfasst von Chun-Ting Yang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massach…. Hauptthemen laut MEDLINE: Natural Language Processing, Electronic Health Records. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS.
Abstract (Originalsprache)
Measuring medication discontinuation in claims data primarily relies on the gaps between prescription fills, but such definitions are rarely validated. This study aimed to establish a natural language processing (NLP)‐based validation framework to evaluate the performance of claims‐based discontinuation algorithms for commonly used medications against NLP‐based reference standards from electronic health records (EHRs). A total of 36,656 patients receiving antipsychotic medications (APMs), benzodiazepines (BZDs), warfarin, or direct oral anticoagulants (DOACs) were identified from the Mass General Brigham EHRs in 2007–2020. These EHR data were linked with 97,900 Medicare Part D claims. An NLP‐aided chart review was applied to determine medication discontinuation from EHR (reference standard). In claims data, discontinuation was defined by having a prescription gap larger than 15–90 days (claims‐based algorithms). Sensitivity, specificity, and predictive values of claims‐based algorithms against the reference standard were measured. The sensitivity and specificity of 90‐day‐gap‐based algorithms were 0.46 and 0.79 for haloperidol, 0.41 and 0.85 for atypical APMs, 0.47 and 0.75 for BZDs, 0.33 and 0.80 for warfarin, and 0.38 and 0.87 for DOACs, respectively. The corresponding estimates for 15‐day‐gap‐based algorithms were 0.68 and 0.55 for haloperidol, 0.59 and 0.62 for atypical APMs, 0.71 and 0.45 for BZDs, 0.61 and 0.49 for warfarin, and 0.58 and 0.64 for DOACs, respectively. Positive predictive values were primarily affected by medication discontinuation rates and less by gap lengths. The overall accuracy of claims‐based discontinuation algorithms differs by medications. This study demonstrates the scalability and utility of the NLP‐based validation framework for multiple medications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
- Hinda and Arthur Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School, Boston, Massachusetts, USA.
- Division of Gerontology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
- Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
ORCID-Profile: Chun-Ting Yang
Förderung
- NIA NIH HHS
Zitieren
APA
Yang, C. T., Ngan, K., Kim, D. H., Yang, J., Liu, J., & Lin, K. J. (2025). Establishing a Validation Framework of Treatment Discontinuation in Claims Data Using Natural Language Processing and Electronic Health Records. Clinical Pharmacology & Therapeutics, 118(1), 138-145. https://doi.org/10.1002/cpt.3650
Vancouver
Yang CT, Ngan K, Kim DH, Yang J, Liu J, Lin KJ. Establishing a Validation Framework of Treatment Discontinuation in Claims Data Using Natural Language Processing and Electronic Health Records. Clinical Pharmacology & Therapeutics. 2025;118(1):138-145. doi:10.1002/cpt.3650
BibTeX
@article{Yang2025,
author = {Yang, Chun-Ting and Ngan, Kerry and Kim, Dae Hyun and Yang, Jie and Liu, Jun and Lin, Kueiyu Joshua},
title = {Establishing a Validation Framework of Treatment Discontinuation in Claims Data Using Natural Language Processing and Electronic Health Records},
journal = {Clinical Pharmacology & Therapeutics},
year = {2025},
volume = {118},
number = {1},
pages = {138--145},
doi = {10.1002/cpt.3650}
}
EUVIMED